A measurable cortical drug effect is different from a validated measure of driving ability or legal capacity.
What the supplied source reports
In a double-blind four-way crossover study, sixteen healthy men received lorazepam, levetiracetam, valproate or placebo. Transcranial magnetic stimulation was paired with muscle and EEG recordings before dosing and at several later times. Lorazepam reduced motor-evoked response amplitude and enhanced long intracortical inhibition under specified stimulation conditions.
Limits of the evidence
The experiment was designed to develop pharmacodynamic biomarkers, not diagnose intoxication or predict crashes. Its small healthy male sample and controlled single exposures differ from clinical patients and mixed-drug cases. Stimulation procedures also influence the measured response.
Implications for forensic interpretation
For expert explanation, separate demonstrated target-related physiology from meaningful functional impairment. Identify the actual task and outcome before using the word impairment. This paper supports sensitivity of experimental excitability measures to lorazepam but supplies no validated threshold for inability to drive, consent or perform a particular activity.
Source and related reading
Source reviewed: Transcranial magnetic stimulation as biomarker of excitability in drug development A randomized doub (PMC9303426). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Lorazepam Case Described Orthostatic Symptoms Without Consistent Threshold Hypotension.
Leave a Reply